Also known as: PPMS
Immunic presented new Phase 2 CALLIPER data at CMSC 2026 showing vidofludimus calcium's favorable effects in progressive MS, including a novel unified disability endpoint. The company also secured $400M in private placement to fund Phase 3 ENSURE studies and commercial preparations.
Immunic reported first-quarter 2026 results and said a $200 million upfront private placement is expected to fund phase 3 ENSURE trials in relapsing MS. The financing could provide up to $400 million in gross proceeds.
AI-powered drugmaker Earendil Labs secured $787 million to advance biologics for autoimmune diseases and cancer, while Immunic locked in up to $400 million to fund Phase 3 trials of its multiple sclerosis therapy.
Phase III FENtrepid trial results show investigational BTK inhibitor fenebrutinib met its primary endpoint of non-inferiority to ocrelizumab in primary progressive MS, with a 12% reduction in disability progression risk and strongest effect on upper limb function.
Immunic announced an oversubscribed private placement of up to $400 million to complete phase 3 trials of vidofludimus calcium in relapsing multiple sclerosis, initiate a phase 3 program in primary progressive MS, and transition to a commercial organization.
Immunic announced an oversubscribed private placement of up to $400 million to complete Phase 3 trials of vidofludimus calcium in relapsing multiple sclerosis, initiate a Phase 3 trial in primary progressive MS, and transition into a commercial organization.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07483450 |
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT07477639 |
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis |
RECRUITING | PHASE1/PHASE2 |
| NCT07426991 |
Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis |
RECRUITING | |
| NCT07280871 |
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care |
NOT_YET_RECRUITING | |
| NCT06900192 |
A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis |
NOT_YET_RECRUITING | PHASE1 |
| NCT05974852 |
Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS |
COMPLETED | |
| NCT05974839 |
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical) |
COMPLETED | |
| NCT05893225 |
Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05349474 |
Metformin Treatment in Progressive Multiple Sclerosis |
COMPLETED | EARLY_PHASE1 |
| NCT05232825 |
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis |
COMPLETED | PHASE3 |
